> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Oncologic Drugs Panel to Review Sutent sNDA
- URL: https://www.fdaweb.com/oncologic-drugs-panel-to-review-sutent-snda/
- Published: 2017-08-07T12:00:00.000Z
- Updated: 2026-09-14T22:39:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139314

*Federal Register* notice: FDA has announced a 9/19 Oncologic Drugs Advisory Committee meeting from 8:30am to 1pm. Panel members will review a C.P. Pharmaceuticals, represented by Pfizer, supplemental NDA for Sutent (sunitinib malate) oral capsules, indicated for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-08-07/pdf/2017-16518.pdf?ref=fdaweb.com).